EXPERIENCE OF PALIVIZUMAB IN PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRAL INFECTION IN PREMATURE CHILDREN WITH BRONCHOPULMONARY DYSPLASIA

Cover Page

Abstract


The data on prophylaxis efficacy of the Palivizumab (synagis) against respiratory syncytial viral infection in premature children with bronchopulmonary dysplasia are shown in the article. No side-effects, good tolerance and decrease of the frequency of bronchopulmonary dysplasia relapses and other viral diseases in whole in such children were registered.




G. A. Alyamovskaya

Correction Centre for Premature Children of the Moscow Scientific Research Institute of Pediatrics and Pediatric Surgery
of the Ministry of Healthcare of the Russian Federation, Moscow, the Russian Federation

Author for correspondence.
Email: galina45@mail.ru

Russian Federation MD, pediatrician, Early Age Department, Federal State Budget Institution, Moscow Scientific Institution of Pediatrics and Children’s’ Surgery, Ministry of Health, Russian Federation Address: 125412, Moscow, Taldomskaya str., 2; Tel.: (495) 483-21-74

E. S. Keshishyan

Correction Centre for Premature Children of the Moscow Scientific Research Institute of Pediatrics and Pediatric Surgery
of the Ministry of Healthcare of the Russian Federation, Moscow, the Russian Federation

Email: ekeshishian@list.ru

Russian Federation PhD, Professor, Head of Center of Correction of Premature Children Correction, Federal State Budget Institution Moscow Scientific Institution of Pediatrics and Children’s’ Surgery, Ministry of Health, Russian Federation Address: 125412, Moscow, Taldomskaya str., 2

  1. Kulichenko T.V. Respiratory syncytial virus infection in children, new research. Pediatricheskaya farmakologiya = Pediatric pharmacology. 2009; 6 (6).133-140.
  2. Ovsyannikov D.Yu. Sistema okazaniya meditsinskoi pomoshchi detyam, stradayushchim bronkholegochnoi displaziei. Ruk-vo dlya praktikuyushchikh vrachei [The System of Care for Children Suffering from Bronchopulmonary Dysplasia. Guideline]. Moscow, MDV, 2010.
  3. Wu S.-Y., Bonaparte J., Pyati S. Palivizumab use in very premature infants in the neonatal intensive care unit. Pediatrics.2004; 114; 554–556.
  4. Eber E., Zach M.S. Long term sequelae of bronchopulmonary dysplasia (chronic lung disease of infancy). Thorax. 2001; 56: 317–323.
  5. Davydova I.V. Formirovanie, techenie i iskhody bronkholegochnoi displazii u detei. Avtoref. diss. … dokt. med. nauk [Formation, Course and Outcome of Bronchopulmonary Dysplasia in Children. Author’s abstract]. Moscow, 2010. 48 p.
  6. Northway W.H.Jr., Rosan R.C., Porter D.Y. Pulmonary disease following respiratory therapy of hyaline membrane discase. N. Engl. J. Med. 1967; 276: 357–368.
  7. Markestad T., Fitzhardinge P.M. Growth and development in children recovering from bronchopulmonary dysplasia. J. Pediatrics. 1981; 98: 597–602.
  8. Mayes L., Perkett E., Stahleman M.T. Severe bronchopulmonary dysplasia: a retrospective review. Acta Paediatrica. 1983; 72 (1–2): 220–229.
  9. Yu V.Y.H., Orgill A.A., Lim S.B., Bajuk B., Astbury J. Growth and development of very low birthweight infants recovering from bronchopulmonary dysplasia. Arch. Dis. Childhood. 1983; 58: 791–794.
  10. The Impact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in highrisk infants. Pediatrics. 1998; 102: 531–537.
  11. Checchia P.A., Nalysnyk L., Fernandes A.W. Checchia PA, Nalysnyk L, Fernandes AW, Mahadevia PJ, Xu Y, Fahrbach K, Welliver RC Sr.. Mortality and morbidity among infants at high risk for severe respiratory syncytial virus infection receiving prophylaxis with palivizumab: a systematic literature review and meta-analysis. Pediatr. Crit. Care Med. 2011; 12 (5): 580–588.
  12. Korsunskii A.A., Ovsyannikov D.Yu., Degtyarev D.N., Yakovleva I.N., Degtyareva E.A., Bokeriya E.L., Keshishyan E.S., Shamsheva O.V., Pavlova E.S., Krsheminskaya I.V., Igityan Z.S., Markhuliya Kh.M., Balashova E.D., Alyamovskaya G.A., Mironyuk O.V., Potapova O.V. Immunization respiratory syncytial virus infection in children at risk of severe course: first results of the implementation of the Moscow program. Pediatricheskaya farmakologiya = Pediatric pharmacology. 2012; 9 (3): 22–30.
  13. Subramanian K.N., Weisman L.E., Rhodes T., Ariagno R, Sánchez PJ, Steichen J, Givner LB, Jennings TL, Top FH Jr, Carlin D, Connor E. Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. MEDI-493 Study Group. Pediatr. Infect. Dis. J. 1998; 17: 110–115.

Views

Abstract - 24

PDF (Russian) - 34

Cited-By


PlumX

Dimensions



Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies